Occoris - Self Activating Smart Inhaler

Occoris - 自激活智能吸入器

• 批准号: EP/N510087/1
• 负责人: Darragh Murnane
• 金额: $ 17.68万
• 依托单位: University of Hertfordshire
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FN510087%2F1
• 关键词: Occoris; Self; Activating; Smart; Inhaler

The ability to target lung deposition to the diseased airways is influenced by the patient's cognitive ability to handle thedevice correctly, his/her inspiratory profile, and the mechanism of aerosolization of the inhaler. This project focuses on thedevelopment of a novel aerosol generation device called Occoris. Unlike conventional pMDIs, Occoris has no need forpropellants and is recyclable. Similar to DPIs, the aerosol is generated on-demand by the patient. However, because thedrug formulation is pre-packaged in pressurized blisters, the aerosolization is self-activating and is not driven by a forcefulinhalation. When the patient inhales, the blister ruptures, and releases a fine aerosol of drug suitable for deep lunginhalation. Occoris therefore has potential for:1. Coordination of drug delivery with inhalation;2. Minimized throat deposition, compared to pMDIs (even breath-actuated pMDIs);3. Minimized pulmonary function-derived variability of lung deposition between patients;4. Consistency of aerosol dose and properties for high-dose DPI products.In this research programme, we will seek to develop a mechanism to target drug aerosols to diseased regions of the lungthrough controlling patient's inspiratory flow rate and the release rate of aerosol particles during an inhalation cycle. Thisunique achievement for DPI drug delivery derives from the novel aerosolization mechanism of the Occoris blister design.Aerosol generation will be studied using a human inhalation simulator to reproduce inhalation profiles recorded from OLDpatients. Drug formulations will be engineered to achieve high dispersibility in studies supported by the development ofadvanced analytical methods that test for chemical stability and compatibility with Occoris components. Blister packingcomponents will be engineered using air-permeable fibre meshes to support the formulations within aluminium blisters thatare designed to rupture when a patient inhales. The knowledge gained from these studies will be translated into productsthat minimize throat deposition and maximize deep lung targeting of therapeutic aerosols for the treatment of lungdiseases.

靶向肺部沉积到患病气道的能力受患者正确处理the夫，他/她的灵感概况以及吸入器雾化机制的认知能力的影响。该项目着重于一种称为occoris的新型气溶胶生成设备的开发。与传统的PMDI不同，Occoris不需要促销剂，并且可回收。与DPI相似，患者在点播中生成气溶胶。但是，由于Thedrug公式是在加压水泡中预先包装的，因此气化是自动激活的，并且不是由有力的Fullinhalation驱动的。当患者吸入患者时，水泡会破裂并释放出适合深lunginhalation的精美气溶胶。因此，Occoris具有：1。吸入药物输送的协调； 2。与PMDI相比（甚至是呼吸呼吸的PMDI）相比，喉咙沉积最小化； 3。最小化肺功能衍生的肺部沉积变异性； 4。高剂量DPI产品的气溶胶剂量和性能的一致性。在本研究计划中，我们将寻求一种机制，将药物气溶胶靶向肺部控制患者的吸气流量和吸入周期期间气溶胶颗粒的释放率的机制。 DPI药物递送的这种企业成就源自Occoris泡出设计的新型雾化机制。将使用人类吸入模拟器研究大赛的生成，以再现从旧患者中记录的吸入曲线。药物制剂将经过设计，以实现高度分散性，该研究由增强分析方法的发展支持，该方法测试化学稳定性和与OCCORIS组件的兼容性。泡沫包装的组件将使用可渗透的纤维网络设计，以支撑铝水泡中的配方，该制剂旨在在患者吸入患者时破裂。从这些研究中获得的知识将被转化为最大程度地减少喉咙沉积的产品，并最大程度地提高治疗性气溶胶的深肺靶向肺炎治疗。